



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 22nd February 2023

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Ms L Prince (LP)	Senior Medicines Management Technician, EL ICB
Dr S Jackson (SJ)	GPwSI in therapeutics
Mr Neil Fletcher (NF)	Director of Pharmacy ELHT
Dr F Shah (FS)	GP/Consultant MFOP & Diabetes

IN ATTENDANCE:

Dr D Corbett	Consultant paediatrician ELHT
--------------	-------------------------------

2023/18: APOLOGIES:

Mrs H Robinson (HR)	Divisional Lead Pharmacist – MEC
---------------------	----------------------------------

2023/19: DECLARATION OF INTEREST

SR declared interest in item 2023-26 [semaglutide included in the document] It was agreed to include the company name to new product requests.

2023/20: MINUTES OF DECEMBER TEAMS MEETING:

Accepted as accurate record.

2023/21: MATTERS ARISING:

2021/101b / 2023/09: ELMMB Membership – to remain on action matrix as a standing item for feedback.

Terms of reference to be updated for primary care, transfer of care issues. Quality and safety measures also need to be captured. VG is looking at ELMMB terms of reference to align with drugs and therapeutic group and secondary care committees. LR met with LSCMMG members to look at using their website to host the ELMMB website as a sub-section'. A review and prioritisation of all ELMMB documents is currently underway. SR mentioned that at the last LSCMMG it was clear that other member areas also felt there



was not enough representation at the LSCMMG meeting for decision making. The primary care and clinician representation needs to be improved.

Action: to remain on action matrix as a standing item for feedback.

2022/156f: Valaciclovir 500mg tablets – minimal prescribing Oct 21 – Sept 22. The change in traffic light status may influence prescribing habits, with a possible increase in the use of valaciclovir. The cost difference per treatment course is approximately £10. Decision to monitor prescribing trend and re-visit. Remove from action matrix.

Resolved

2022/199: Weight management pathways and semaglutide – pathway issues have been flagged and will be sent to lead ICB commissioner when they are appointed. Remove from action matrix.

Resolved

2023/05a: Dymista® - Dr Corbett, a consultant in the paediatric asthma clinic was in attendance. He explained that he has patients with severe allergic rhinitis that have had failed treatment with Flixotide, mometasone and Beconase. They are then referred to the allergy clinic at Manchester Children's Hospital who often prescribe Dymista® or Avamys® nasal spray. These are Black traffic light in Lancashire and can't be prescribed. Therefore, this cohort of patients must obtain further supplies from Manchester. LR mentioned that there have been no trials on this unique cohort of patients. It was agreed that since this applies to a small and specific defined population it would be more appropriate to allow prescribing within the hospital setting following initiation in tertiary care. This would be RED traffic light. Dr Corbett will feedback internally via the comments line and will provide specific criteria for the continuation of therapy etc. For use in paediatric patients only as defined.

Resolved: Dymista® to be given RED traffic light for this specific group of paediatric patients only, with severe allergic asthma, on approval from a tertiary centre.

2023/22: Formulary Updates

- a. **Dymista®:** see matters arising item 2023/05a
- b. **Nizatidine, famotidine and esomeprazole:** request for traffic light to be Green.

Resolved: ELMMB formulary will be updated accordingly

2023/23 LSCMMG Consultations – March 2023 [deadline 02/03/23]

- a. Melatonin prescribing guidance.
- b. COPD guideline: comments from group included the document being too big, not user friendly and needs to be streamlined.
- c. Nephrotrans, metabolic acidosis in adults with chronic renal impairment – **recommended BLACK** for the treatment of metabolic acidosis and for maintenance treatment against recurrence of metabolic acidosis in adults with chronic renal impairment.

All documents have been circulated to appropriate directorate.

Resolved: Comments to be sent to LSCMMG.



2023/24 LSCMMG Recommendations – January 2023

- a. LSCMMG ONS Guideline – Updated
- b. Psoriasis Biologic Treatment Pathway - Updated
- c. Olopatadine hydrochloride 600 micrograms / mometasone furoate monohydrate 25 micrograms per actuation nasal spray (Ryaltris®) – Updated.
- d. Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) (Sativex®) For Refractory Neuropathic Pain – Updated

Resolved: items acknowledged by ELMMB. Website will be updated accordingly.

2023/25 Pharmacy and Medicines Policy Task and Finish Group recommendations sheet (*formally SCC*) – January 2023

None this month

2023/26 Other Items

GLT2i dosing considerations according to eGFR when treating T2D, HF or CKD – Draft version.

SJ commented that the document had not been written in accordance with NICE guidance and was more aligned to manufacturer licensing recommendations rather than the indication being in line with NICE guidelines.

It was agreed that the document would be re-visited and brought back to the next meeting. SJ to send comments to SR and AB.

ACTION: document to be amended in line with NICE guidance and brought back

2023/27 NICE Guidance – January 2023

NG209: Tobacco: preventing uptake, promoting quitting, and treating dependence. Updated 16th January 2023.

CG103: Delirium: prevention, diagnosis and management in hospital and long-term care. Updated 18th January 2023

CG124: Hip fracture, management. Updated 6th January 2023

2023/28 NICE Recommendations – January 2023

Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy recommended by NICE

TA855

NHSE Commissioned

Traffic Light RED

Upadacitinib for treating moderately to severely active ulcerative colitis recommended by NICE **TA856**

ICS Commissioned, Blueteq

Traffic Light RED

Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma recommended by NICE **TA857**

NHSE Commissioned

Traffic Light RED



Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma recommended by **NICE TA858**.

NHSE Commissioned

Traffic Light RED

Angiotensin II for treating vasopressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) not recommended by **NICE TA859**

Traffic Light BLACK

Maribavir for treating refractory cytomegalovirus infection after transplant recommended by **NICE TA860**.

NHSE Commissioned

Traffic Light RED

2023/29 NICE Highly Specialised Technologies – January 2023

None this month

2023/30 EAMS (Early access to medicines scheme) – January 2023

None this month

Standing Items:

2023/31 For Action/Information: Lancashire & South Cumbria Medicines Management Group (LSCMMG)

DRAFT LSCMMG minutes 12.01.23

Resolved: acknowledged

2023/32 For Action/Information: Lancashire & South Cumbria FT Drugs and Therapeutics Committee

Minutes and open action tracker from 26th January currently not available.

2023/33 For Action/Information: Antimicrobial Stewardship Committee (ASC)

November 2022 minutes 22.11.22

January 2023 minutes not yet ratified.

Any other Business

Further meetings will be arranged up to June 2023

DATE OF NEXT MEETING – Wednesday 15th March 2023 12.30pm via ‘Microsoft Teams’



**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 22nd February 2023

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2021/101b and 2023/09	ELMMB Membership A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will require review as a result of that. Await full ICB structure	LR/VG	Mar 23
2023/26	GLT2i dosing considerations according to eGFR when treating T2D, HF or CKD – Draft version. Version to be updated in line with NICE guidance. SJ to email comments to be reviewed by AF and bring back for approval	SJ/AF	Mar 23